New Clinical Trial for BRCA1+ Patients

WCCA is very excited to announce the availability of a new clinical trial at our practice for women with the BRCA1 mutation. We are the only practice in the area to offer patients the opportunity to participate in this NRG Oncology study.

NRG-CC008, also known as the SOROCk Trial, is a clinical trial available to a particular group of women with inherited BRCA1 mutations. For these pre-menopausal women, the study is testing whether removal of just the fallopian tubes, with the plan to remove the ovaries at a later time, can reduce the risk of ovarian cancer to the same degree as the usual standard of care of removing both the ovaries and fallopian tubes. Surgical removal of both ovaries and fallopian tubes very effectively reduces the risk of ovarian cancer in most women.

Researchers believe that most “ovarian” cancers first begin in the fallopian tubes, suggesting that removing only the fallopian tubes may be as good as removing both the fallopian tubes and ovaries in preventing the development of ovarian cancer, while avoiding surgically induced menopause. This has never been formally tested in a clinical trial. The study will also look at how women on the study feel about their quality of life.

More information about this particular study is located on